Related Experiment Video

Updated: Nov 28, 2025

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.3K

TAM receptors and their ligand-mediated activation: Role in atherosclerosis

Bishuang Cai1, Canan Kasikara2

  • 1Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

International Review of Cell and Molecular Biology
|November 25, 2020
PubMed

Insights

TAM receptors (Tyro3, Axl, MerTK) are crucial for clearing apoptotic cells and resolving inflammation. Targeting these receptors and specialized pro-resolving mediators (SPMs) offers therapeutic potential for atherosclerosis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • TAM family tyrosine kinase receptors (Tyro3, Axl, MerTK) are key mediators of efferocytosis.
  • These receptors play a role in regulating inflammatory responses and diseases.
  • Emerging evidence highlights their involvement in inflammation resolution and specialized pro-resolving mediator (SPM) biosynthesis.

Purpose of the Study:

  • To discuss the central roles of TAM signaling in atherosclerosis.
  • To focus on TAM receptor regulation of efferocytosis and inflammation resolution.
  • To highlight the therapeutic potential of SPMs in atherosclerosis.

Main Methods:

  • Review of recent studies on TAM signaling.
  • Analysis of TAM receptor function in efferocytosis.
  • Exploration of SPM roles in inflammation resolution.

Main Results:

  • TAM receptors are critical for efferocytosis by antigen-presenting cells.
  • TAM signaling modulates inflammatory responses and contributes to inflammation resolution.
  • SPMs are involved in the regulation of atherosclerosis progression.

Conclusions:

  • TAM signaling is central to efferocytosis and inflammation resolution in atherosclerosis.
  • Targeting TAM receptors and SPMs presents a promising therapeutic strategy for blocking atherosclerosis progression.
Keywords:
AtherosclerosisEfferocytosisInflammation resolutionMerTK cleavageSpecialized pro-resolving mediatorsTAM

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.5K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

765

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
503
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.5K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.5K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.1K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
16.6K